Introduction
============

Arboviruses are predominantly RNA viruses that replicate in haematophagous (blood-sucking) arthropod vectors such as ticks, mosquitoes and other biting flies to maintain their transmission cycle \[[@r1]\]. Human disease outbreaks caused by arboviruses have increased in prevalence since the 2000's, led by the spread of mosquito-borne arboviruses such as chikungunya (CHIKV), dengue (DENV), West Nile (WNV), yellow fever (YFV) and Zika (ZIKV) viruses across both hemispheres \[[@r2]\]. CHIKV and DENV are of particular global health concern, as they have lost the need for enzootic amplification and consequently have caused extensive epidemics \[[@r3]\].

CHIKV is a single-stranded positive-sense RNA virus of the alphavirus genus, which causes the debilitating arthritic disease, chikungunya \[[@r4]\]. It has spread globally and been designated a serious emerging disease by the World Health Organization \[[@r5]\]. Outbreaks of CHIKV since 2005 have been associated with increased morbidity and possibly mortality \[[@r6],[@r7]\].

DENV, which causes dengue, is a single-stranded positive-sense RNA virus of the flavivirus genus and the most prevalent human arboviral pathogen. Dengue occurs following infection with one of four DENV serotypes (DENV1--4). A minority of cases develop acute haemorrhagic manifestations and multi-organ failure. Despite DENV cases being under-reported, a 143.1% increased global incidence was estimated between 2005 and 2015 \[[@r8]\]. Approximately 500,000 DENV infected patients worldwide require hospitalisation annually \[[@r9]\].

Both CHIKV and DENV are predominantly transmitted to humans via *Aedes* species mosquitoes, particularly *Ae. aegypti* and *Ae. albopictus* \[[@r10],[@r11]\], and share clinical presentations of arthralgia, headache, high fever, myalgia and rash. Circulation of CHIKV, DENV (and other arboviruses) in the same areas leads to challenges in differential diagnosis, especially in endemic regions in which diagnosis is predominantly symptom-based \[[@r12]\]. Additionally, reports of arboviral coinfections are increasingly common \[[@r13]-[@r16]\].

Metagenomic RNA sequencing allows for identification of multiple pathogens within a sample in a non-targeted and unbiased manner. It has identified causative agents in outbreaks, e.g. Lujo virus in South Africa \[[@r17]\], Bundibugyo ebolavirus in Uganda \[[@r18]\] and lead to novel virus discovery such as a rhabdovirus causing haemorrhagic fever in central Africa \[[@r19]\]. It also provides genomic information for typing and surveillance. Real-time genomic surveillance was facilitated on-site by the portable Oxford Nanopore MinION sequencer during the 2014--16 Ebola virus (EBOV) epidemic in West Africa and the 2015-16 ZIKV outbreak in the Americas \[[@r20]-[@r23]\] for epidemiological and transmission chain investigations \[[@r24]\]. In both examples, an amplicon sequencing approach was used, but viruses and bacteria from clinical, environmental and vector samples have been sequenced using metagenomic approaches on the MinION \[[@r25]-[@r28]\]. Metagenomic sequencing of CHIKV was demonstrated in principle on the MinION by Greninger et al. in 2015 reporting the detection of CHIKV from a human blood sample \[[@r28]\]. Additionally, Illumina-based metagenomics identified CHIKV coinfections within a ZIKV sample cohort \[[@r29]\], with the high proportion of CHIKV reads present making it a promising target for the approach.

In this study we set out to test the feasibility of direct metagenomic sequencing of DENV and CHIKV genomes from a cohort of clinical serum and plasma samples across a representative range of viral loads. The objective was to assess the proportion of viral nucleic acid relative to patient/background present in each sample and determine the sequencing limits for whole genome retrieval using both the laboratory-based Illumina technology and the portable MinION platform.

Methods
=======

Sample collection and nucleic acid extraction
---------------------------------------------

Twenty-six routine diagnostic samples, nine plasma and 17 serum, were obtained from the Rare and Imported Pathogens Laboratory (RIPL), Public Health England (PHE), Porton Down. All had previously tested positive by real-time reverse transcription-PCR (qRT-PCR) for chikungunya or dengue virus, with a maximum cut-off value of cycle threshold (Ct) 35. These samples had been selected based on their Ct values, among a larger set of 441 samples, so as to represent a Ct clinical range. Total nucleic acid was extracted from 140 μL of each using the QIAamp viral RNA kit (Qiagen, Hilden, Germany) replacing carrier RNA with linear polyacrylamide and eluting in 60 µL elution buffer provided in the kit, followed by treatment with TURBO DNase (Thermo Fisher Scientific, Waltham, United States (US)) at 37 °C for 30 min. RNA was purified and concentrated to 8 μL using the RNA Clean and Concentrator-5 kit (Zymo Research, Irvine, US).

Molecular confirmation and quantification
-----------------------------------------

Drosten et al. \[[@r30]\] and Edwards et al. \[[@r31]\] RT-PCR assays were used for confirmation of DENV and CHIKV respectively. RNA oligomers were used as standards for genome copy quantitation.

Metagenomic cDNA reparation
---------------------------

Complementary DNA (cDNA) was prepared using a Sequence Independent Single Primer Amplification (SISPA) approach adapted from Greninger et al. \[[@r28]\]. Reverse transcription and second strand cDNA synthesis were as described \[[@r28]\]. cDNA amplification was performed using AccuTaq LA (Sigma, Poole, United Kingdom), in which 5μL of cDNA and 1 μL (100 pmol/μL) Primer B (5′-GTTTCCCACTGGAGGATA-3′) were added to a 50 μL reaction, according to manufacturer\'s instructions. PCR conditions were 98 °C for 30s, followed by 30 cycles of 94 °C for 15 s, 50 °C for 20 s, and 68 °C for 5 min, and a final step of 68 °C for 10 min. Amplified cDNA was purified using a 1:1 ratio of AMPure XP beads (Beckman Coulter, Brea, California (CA)) and quantified using the Qubit High Sensitivity dsDNA kit (Thermo Fisher, Waltham, US).

MinION library preparation and sequencing
-----------------------------------------

MinION sequencing libraries were prepared using total amplified cDNA of each sample to a maximum of 1 µg. Oxford Nanopore kits SQK-NSK007 or SQK-LSK208 (2D), SQK-LSK308 (1D^2^) and SQK-RBK001 (Rapid) were used and each sample was run individually on the appropriate flow cell (FLO-MIN105, FLO-MIN106 or FLO-MIN107) using the 48hr run script. Base calling was performed using Metrichor (ONT) for SQK-NSK007 and SQK-LSK208 or Albacore v1.2 for SQK-LSK308 and SQK-RBK001. Poretools \[[@r32]\] was used to extract FASTQ files from Metrichor FAST5 files.

Illumina library preparation and sequencing
-------------------------------------------

Nextera XT V2 kit (Illumina) sequencing libraries were prepared using 1.5 ng of amplified cDNA as per manufacturer\'s instructions. Samples were multiplexed in batches of a maximum of 16 samples per run and sequenced on a 2x150 bp-paired end Illumina MiSeq run, by Genomics Services Development Unit, PHE.

Data handling
-------------

BWA MEM v0.7.15 \[[@r33]\] was used to align reads to the following references (GenBank ID): DENV Serotype 1 (NC_001477.1), DENV Serotype 2 (NC_001474.2), DENV Serotype 3 (NC_001475.2), DENV Serotype 4 (NC_002640.1) and CHIKV (NC_004162.2) using -x ont2d mode for Nanopore and MEM defaults for Illumina reads. Samtools v1.4 \[[@r34]\] was used to compute percentage reads mapped and coverage depth. Bedtools v2.26.0 \[[@r35]\] was used to calculate genome coverage at 10x and 20x. Mapping consensuses for Illumina were generated using in-house software QuasiBam \[[@r36]\] and for MinION using a simple pileup with bases called at a minimum depth of 20x and 70% support fraction. Nanopolish variants \[[@r24],[@r37]\] was used in consensus mode to compute an error-corrected consensus sequence from the Rapid kit data. Taxonomic classification was performed using Kraken (0.10.4-beta) \[[@r38]\] and a locally built database populated with all RefSeq bacterial, viral, and archaeal genomes plus additional sequences \[[@r39]\]. De novo assemblies were generated using Spades 3.8.2 \[[@r40]\] in combination with SSPACE Standard v3.0 \[[@r41]\] for Illumina generated sequences and Canu v1.6 \[[@r41],[@r42]\] for Nanopore sequences (settings: corOutCoverage = 1,000; genomeSize = 12,000; minReadLength = 300, minOverlapLength = 50).

Consensus sequences for all samples tested are available in Genbank, raw fast5 files from 1D2 and 1D data (viral reads only) are deposited in SRA (Both under BioProject PRJNA508296).

Results
=======

Metagenomic Illumina sequencing
-------------------------------

A total of 73 samples tested during 2016 in RIPL diagnostic laboratories, PHE Porton Down, were positive by qRT-PCR for CHIKV, and 368 were positive for DENV. Median Ct for CHIKV was 26.1, for DENV it was 26.8. For each virus, samples representing the range of viral titres seen during 2016 were selected, based on qRT-PCR Ct value ([Figure 1](#f1){ref-type="fig"}). CHIKV samples selected (n = 14) ranged from Ct 14.72 to Ct 32.57, corresponding to 10^10^ and 10^5^ genome copies per mL of plasma or serum. DENV samples selected (n = 12) ranged from Ct 16.29 to Ct 31.29, corresponding to 10^9^ and 10^5^ genome copies per mL ([Table 1](#t1){ref-type="table"}). To measure the proportion of viral nucleic acid present relative to host/background and assess genome coverage, all samples were processed as described in methods and Illumina sequenced ([Table 1](#t1){ref-type="table"}). The proportion of total reads mapping to the respective viral reference was high for both viruses ([Figure 2](#f2){ref-type="fig"}). In some low Ct samples, over 90% of reads mapped to the viral reference and proportions over 50% were still observed at mid-Ct range. The lowest proportions observed were 5.03% and 0.47% for CHIKV and DENV respectively ([Table 1](#t1){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}). The majority of samples returned over 95% genome coverage at 20x (21/26 samples) and over 98% genome coverage at 10x (20/26 samples). Irrespective of lower mapping percentages in high Ct value samples, genome coverage of 88.5% (20x) and 89.4% (10x) for CHIKV and 75.0% (20x) and 77.8% (10x) for DENV was observed.

![Cycle threshold (Ct) values distribution of chikungunya (n = 73) and dengue virus (n = 368) positive samples from the Rare and Imported Pathogens Laboratory, Public Health England, United Kingdom, 2016 (n = 441 total samples)](1800228-f1){#f1}

###### Description of samples positive for chikungunya and dengue virus by real-time reverse transcription-PCR with corresponding Illumina mapping data, United Kingdom, 2017^a^ (n = 26 samples)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample     Ct value   Estimated genome copy number in the sample (/mL)   Sample type   Total reads\   \% reads mapping to reference viral genome   \% 20x coverage   \% 10x coverage   Reference virus^c^   Reference\
                                                                                         (R1 + R2)^b^                                                                                                         size (nts)
  ---------- ---------- -------------------------------------------------- ------------- -------------- -------------------------------------------- ----------------- ----------------- -------------------- ------------
  CHIKV 1    14.72      2.12E + 10                                         Plasma        1,113,560      78.32                                        99.59             99.72             CHIKV                11,826

  CHIKV 2    20.06      5.49E + 08                                         Serum         1,278,624      98.48                                        99.14             99.47             CHIKV                11,826

  CHIKV 3    21.41      2.18E + 08                                         Plasma        1,391,258      95.23                                        98.86             99.37             CHIKV                11,826

  CHIKV 4    22.74      8.76E + 07                                         Plasma        888,968        19.16                                        97.08             97.32             CHIKV                11,826

  CHIKV 5    23.77      4.33E + 07                                         Plasma        1,357,606      97.13                                        99.16             99.58             CHIKV                11,826

  CHIKV 6    25.4       1.42E + 07                                         Serum         3,236,848      34.88                                        97.80             98.40             CHIKV                11,826

  CHIKV 7    25.76      1.11E + 07                                         Plasma        3,748,070      72.77                                        99.04             99.56             CHIKV                11,826

  CHIKV 8    28.17      2.13E + 06                                         Plasma        1,499,952      28.41                                        98.69             99.00             CHIKV                11,826

  CHIKV 9    30.08      5.76E + 05                                         Serum         1,035,026      6.66                                         95.98             98.22             CHIKV                11,826

  CHIKV 10   30.37      4.72E + 05                                         Serum         1,575,222      16.84                                        97.39             98.01             CHIKV                11,826

  CHIKV 11   30.66      3.87E + 05                                         Serum         1,143,054      13.52                                        95.36             96.96             CHIKV                11,826

  CHIKV 12   30.95      3.17E + 05                                         Serum         1,507,380      10.93                                        96.11             96.52             CHIKV                11,826

  CHIKV 13   32.2       1.35E + 05                                         Serum         1,323,920      5.03                                         88.47             89.38             CHIKV                11,826

  CHIKV 14   32.57      1.05E + 05                                         Serum         1,479,404      21.72                                        96.32             96.93             CHIKV                11,826

  DENV 1     16.29      4.21E + 09                                         Plasma        439,292        93.44                                        99.51             99.58             DENV 1               10,735

  DENV 2     16.85      2.83E + 09                                         Serum         513,472        92.56                                        99.40             99.58             DENV 1               10,735

  DENV 3     17.67      1.58E + 09                                         Plasma        738,814        92.53                                        99.58             99.58             DENV 2               10,723

  DENV 4     18.20      1.09E + 09                                         Serum         477,368        93.97                                        98.73             99.12             DENV 2               10,723

  DENV 5     19.73      3.67E + 08                                         Serum         915554         89.65                                        99.14             99.40             DENV 2               10,723

  DENV 6     21.22      3.61E + 07                                         Serum         3,587,926      83.87                                        99.68             99.69             DENV 4               10,649

  DENV 7     23.76      2.11E + 07                                         Serum         4,146,678      2.17                                         86.99             89.13             DENV 1               10,735

  DENV 8     24.8       1.01E + 07                                         Serum         777,264        69.23                                        99.56             99.58             DENV 3               10,707

  DENV 9     25.28      7.17E + 06                                         Plasma        787,728        26.97                                        98.77             98.81             DENV 2               10,723

  DENV 10    26.98      2.15E + 06                                         Serum         596,240        6.58                                         93.47             93.97             DENV 3               10,707

  DENV 11    28.69      6.39E + 05                                         Serum         1,034,698      3.73                                         94.44             94.70             DENV 1               10,735

  DENV 12    31.29      1.01E + 05                                         Serum         1,374,766      0.47                                         71.46             77.76             DENV 1               10,735
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus.

^a^The Illumina mapping data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

^b^ 'R1 + R2' indicates paired-end sequencing.

^c^ For DENV the serotype is also indicated.

![Proportion of reads mapping to the appropriate viral reference sequence and proportion of reference genome sequenced at minimum 20-fold coverage in each chikungunya or dengue virus positive sample, United Kingdom, 2017^a^ (n = 26 samples)](1800228-f2){#f2}

Metagenomic MinION sequencing
-----------------------------

Four representative samples for each virus were selected for Nanopore sequencing ([Table 2](#t2){ref-type="table"}).

###### Description of chikungunya and dengue virus positive samples by real-time reverse transcription-PCR and corresponding Nanopore sequencing data, United Kingdom, 2017^a^ (n = 8 samples)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample    Ct value   cDNA amount used for the library (ng)   Sequencing kit\    Flow cell\   1D total bp   1D total\   1D mean\           1D max\
                                                               (2D kit version)   (FLO-)                     reads       read length (nt)   read length (nt)
  --------- ---------- --------------------------------------- ------------------ ------------ ------------- ----------- ------------------ ------------------
  CHIKV 1   14.7       431.5                                   SQK-NSK007         MIN105       1.51E + 08    267,171     564                92,712

  CHIKV 3   21.4       928.8                                   SQK-LSK208         MIN106       1.63E + 09    1,891,028   862                99,031

  CHIKV 4   22.7       113.4                                   SQK-NSK007         MIN105       1.74E + 08    216,493     805                125,387

  CHIKV 9   30.1       212.4                                   SQK-LSK208         MIN106       2.12E + 09    3,481,358   608                121,711

  DENV 1    16.3       1,626.0                                 SQK-NSK007         MIN105       2.42E + 08    284,622     851                115,494

  DENV 2    16.9       1,626.0                                 SQK-NSK007         MIN105       1.55E + 08    203,700     760                52,157

  DENV 6    21.2       475.0                                   SQK-LSK208         MIN106       1.22E + 09    1,377,721   886                118,733

  DENV 11   28.7       65.8                                    SQK-LSK208         MIN106       7.07E + 08    1,111,566   636                119,438
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Ct: cycle threshold.

^a^ The Nanopore data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

[Figure 3](#f3){ref-type="fig"} shows percentages of reads mapping to viral reference, which were generally concordant with the Illumina data, although a slight decrease is observed across the range of Ct values. In the Nanopore data, the highest mapped read percentages observed were 85.12% and 72.14% for CHIKV3 and DENV 2 respectively, compared with 95.23% and 92.56% in the Illumina data from the same samples. While in high Ct samples the viral proportion drops to 4.08% for CHIKV 9 and 2.90% for DENV 11, from 6.66% and 3.73% in the Illumina data.

![Comparison of Nanopore and Illumina results, as to proportions of reads mapping to the appropriate reference viral sequence, and proportions of reference genome sequenced at minimum 20-fold coverage, United Kingdom, 2017^a^ (n = 8 samples)](1800228-f3){#f3}

Despite the decrease in proportion of mapped viral reads, comparable genome coverage is observed at both 20x and 10x ([Figure 3](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}) and is even increased compared with Illumina data at lower viral titres, e.g. 100% at 20x for CHIKV 9 compared with 95.98% in the Illumina data and 95.25% for the high Ct DENV 11 sample, which generated 94.44% coverage from the Illumina data. Average read lengths in Nanopore data ranged from 564 to 886 bp ([Table 2](#t2){ref-type="table"}).

###### Summary of Nanopore mapping data on chikungunya and dengue virus positive samples by real-time reverse transcription-PCR, United Kingdom, 2017^a^ (n = 8 samples)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample    Ct value   Total\      \% reads mapping to appropriate viral sequence   \% 20x\    20x genome\   \% 10x coverage   Reference^b^   Reference size (nt)   Max de novo contig (nt)
                       reads                                                        coverage   length (nt)                                                          
  --------- ---------- ----------- ------------------------------------------------ ---------- ------------- ----------------- -------------- --------------------- -------------------------
  CHIKV 1   14.7       267,171     65.1                                             98.57      11,658        99.2              CHIKV          11,826                5,263

  CHIKV 3   21.4       1,891,028   85.1                                             99.76      11,798        99.9              CHIKV          11,826                10,793

  CHIKV 4   22.7       216,493     11.6                                             94.11      11,130        97.2              CHIKV          11,826                4,256

  CHIKV 9   30.08      3,481,358   4.08                                             100        11,826        100               CHIKV          11,826                9,860

  DENV 1    16.3       284,622     71.3                                             99.9       10,719        99.9              DENV 1         10,735                8,281

  DENV 2    16.9       203,700     72.1                                             99.6       10,692        99.6              DENV 1         10,735                10,157

  DENV 6    21.2       1,377,721   71.1                                             99.9       10,634        99.9              DENV 4         10,649                7,877

  DENV 11   28.7       1,111,566   2.9                                              95.3       10,226        96.3              DENV 1         10,735                4,699
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus.

^a^ The Nanopore data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

^b^ For DENV the serotype is also indicated.

[Figure 4](#f4){ref-type="fig"} shows coverage depth of reads mapped across the relevant genome for each sample sequenced by both Illumina and Nanopore. Read levels are not normalised thus actual depth is a function of total reads sequenced, but the pattern of coverage seen is highly similar suggesting it is more dependent upon the SISPA methodology than sequencing library preparation. From Nanopore consensus genome sequences, between 99.93% and 100% of bases called per sample agreed with the Illumina generated sequence.

![Coverage depth across the chikungunya or dengue viral genome, United Kingdom, 2017^a^ (n = 8 samples)](1800228-f4){#f4}

Metagenomic data analysis and coinfection identification
--------------------------------------------------------

To test the applicability of a metagenomic analysis approach to the data, we assessed read taxonomic classification using Kraken ([Figure 5](#f5){ref-type="fig"}). The distribution of reads classified as CHIKV, DENV, other viruses, bacteria, and archaea/eukaryota show a similar pattern for Illumina and Nanopore data. The proportion of unclassified reads for each sample increased with Ct value, as the proportion of human origin reads is higher and the human genome is not represented in our Kraken database. A decrease in the percentage of CHIKV and DENV classified reads is observed for MinION data compared with Illumina, but was sufficient to identify the correct predominant virus in all samples.

![Kraken classification of reads from metagenomic sequencing in (A) chikungunya and (B) dengue real-time reverse transcription-PCR positive samples, United Kingdom, 2017^a^ (n = 8 samples)](1800228-f5){#f5}

Kraken analysis also allowed for the identification of a DENV coinfection in sample CHIKV 3, the consensus sequence of which was unique in the sample set, eliminating cross-contamination from the DENV positive samples as potential source. Kraken classified 0.08% of Illumina reads and 0.15% of MinION reads as DENV. Using reference mapping to validate the finding, 0.22% of Illumina reads and 0.43% of MinION reads mapped to a DENV-1 reference genome. Genome coverage at 20x of 99.73% and 95.99% was achieved for the primary CHIKV and secondary DENV coinfection respectively, with a single MinION flow cell.

De novo assembly
----------------

De novo assembly of the data was attempted using Canu \[[@r42]\] and contigs identified using Basic Local Alignment Search Tool against a Nt database (BLASTn). [Table 3](#t3){ref-type="table"} lists the longest viral contig length identified in each sample, ranging from 4.2 Kb (36% of reference genome size) to 10.8 Kb (91%) for CHIKV and 4.7 Kb (44%) to 10.1 Kb (95%) for DENV. Identification of the pathogen present without prior knowledge would have therefore been possible for all samples.

Updated MinION library kits
---------------------------

We repeated the sequencing of the coinfected CHIKV 3 sample using the MinION 1D^2^ (SQK-LSK308) and Rapid (SQK-RBK001) kits, currently the most accurate and the fastest library preparation kits available, respectively. Using the 1D^2^ kit 74.5% of reads generated mapped to CHIKV and 0.37% to DENV, while from the Rapid kit the result was 66.26% and 0.29% respectively (both lower than observed in the 2D chemistry). Coverage at 20x for CHIKV was above 99% for both kits, and for DENV was 95.04% from the 1D^2^ and 81.09% from the Rapid kit ([Table 4](#t4){ref-type="table"}). Coverage depth pattern across the genome for both viruses ([Figure 6](#f6){ref-type="fig"}) was similar for all library kits tested. Near-maximum coverage for both viruses was obtained within 30 min with the 2D kit, 8 min with the 1D^2^ kit and 85 min with the Rapid kit (Supplementary Figure 1). De novo assembly ([Table 4](#t4){ref-type="table"}) produced best CHIKV contigs of 10.7, 11.3 and 11.4 Kb for the 2D, 1D^2^ and Rapid libraries respectively and the longest contigs generated for DENV were 7.5, 2.2 and 4.2 Kb.

###### Comparison of Nanopore mapping data across library kits, United Kingdom, 2017^a^ (n = 8 samples)

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Platform       Kit\          Flow cell\   Virus\       Total\       \% reads\   \% 20x\    \% 10x\    Reference^b^   Reference\   Max\
                 information   (FLO-)       identified   reads (nt)   mapping     coverage   coverage                  size (nt)    de novo contig (nt)
  -------------- ------------- ------------ ------------ ------------ ----------- ---------- ---------- -------------- ------------ ---------------------
  Illumina       Nextera XT    NA           CHIKV        1,391,258    95.23       98.86      99.37      CHIKV          11,826       7,321

  Illumina       Nextera XT    NA           DENV         1,391,258    0.22        63.66      77.82      DENV1          10,735       6,613

  MinION 2D      SQK-LSK208    MIN106       CHIKV        1,891,028    85.12       99.73      99.91      CHIKV          11,826       10,793

  MinION 2D      SQK-LSK208    MIN106       DENV         1,891,028    0.43        95.99      96.09      DENV1          10,735       7,549

  MinION 1D^2^   SQK-LSK308    MIN107       CHIKV        5,080,906    74.50       99.94      100        CHIKV          11,826       11,369

  MinION 1D^2^   SQK-LSK308    MIN107       DENV         5,080,906    0.37        95.04      96.42      DENV1          10,735       2,199

  MinION Rapid   SQK-RBK001    MIN106       CHIKV        611,110      66.26       99.66      99.68      CHIKV          11,826       11,473

  MinION Rapid   SQK-RBK001    MIN106       DENV         611,110      0.29        81.09      90.83      DENV1          10,735       4,227
  -------------------------------------------------------------------------------------------------------------------------------------------------------

CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus. NA: not applicable.

^a^Results presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

^b^ For DENV the serotype is also indicated.

![Comparison of genome coverage depth across the chikungunya virus or dengue virus genome for different sequencing library preparation methods in a sample coinfected with dengue and chikungunya viruses, United Kingdom, 2017^a^ (n = 1 sample)](1800228-f6){#f6}

The 1D data from the Rapid kit was sufficient to call a consensus from 11,647/11,826 bases of the CHIKV reference with 179/11,826 bases called as ambiguous or too low coverage. All bases called were concordant with the Illumina consensus. A polishing step using Nanopolish \[[@r37]\] with a subset of the mapped reads (ca 100x coverage depth) significantly reduced ambiguous calls to 90/11,826, introducing a single disagreement with the Illumina consensus (99.99% concordance). Despite considerably greater read depth, the 1D^2^ kit called only 11,082/11,826 due to a higher proportion, 744/11826, of ambiguous base calls, suggesting 1D reads are most suitable for this approach.

Discussion
==========

These results clearly show that there are considerable levels of viral nucleic acid present in a large proportion of CHIKV and DENV qRT-PCR positive clinical samples, and demonstrate that relatively modest metagenomic sequencing is capable of elucidating significant portions of viral genome even for samples with Ct values at the higher end of clinical range. A decreased Ct value coincided with an increased proportion of viral reads, with a considerable level of variation between samples, likely because of the total level of non-viral host/background nucleic acid present due to variability between patients or in sample handling during collection, storage and testing. For example, the two lowest viral titre CHIKV samples (13 and 14) have similar Ct values (32.2 and 32.57) but varied significantly in the proportion of viral reads (5.03% and 21.72%). The 5.03% viral reads in CHIKV13 is the lowest for CHIKV, yet still sufficient to generate 88.5% of the CHIKV genome at 20x depth from just ca 662,000 paired-end Illumina reads. This amount of genomic information is highly informative and further sequencing would likely increase coverage. Only seven of the 73 total CHIKV diagnostic samples tested in 2016 had a Ct greater than 32.2 (including sample CHIKV14) ([Table 1](#t1){ref-type="table"}), which suggests that for the majority (\> 90%) of CHIKV PCR positive samples, viral load is sufficient for genome sequencing directly from patient samples without further viral enrichment beyond a simple DNAse digestion ([Figure 1](#f1){ref-type="fig"}). The lowest viral read proportion observed in the DENV samples was 0.47% in DENV12, Ct 31.29, which generated 71.5% coverage at 20x depth (increased to 77.8 at 10x depth) from just 687,000 paired end Illumina reads and allowed for DENV serotype identification. Only 62 of 368 DENV cases in 2016 had a higher Ct, predicting that \> 80% of PCR positive DENV samples have a viral load sufficient for genome sequencing ([Figure 1](#f1){ref-type="fig"}). These estimates are based on Ct range distribution from a single year, results may vary from year to year.

The high yield of viral sequences from clinical CHIKV and DENV samples make the exciting prospect of metagenomic MinION viral whole-genome-sequencing feasible, even for lower viral titre samples. Evaluating this on a representative subset of our samples demonstrates that viral read proportions are in general agreement with that seen for Illumina sequencing, predicting a similar proportion of qRT-PCR positive patient samples would be suitable for direct metagenomic sequencing on the MinION. Differences in precise proportions of viral reads seen between Illumina and MinION are likely due to inter-library variation. Differences in genome coverage achieved are due to both differences in total reads generated per sample (not normalised between platforms) as well as differences in average read length. Of the samples tested on the MinION, the lowest titre samples CHIKV 9 and DENV 11 both generated near complete genome coverage.

We repeated the sequencing of the coinfected CHIKV 3 sample using the MinION 1D^2^ (SQK-LSK308) and Rapid (SQK-RBK001) kits. A reduction in viral proportion of total reads was observed compared with the 2D kit, which may be due partly to the extended storage time of the original samples before retesting. In the case of the 1D^2^ kit, the lower proportion was outweighed by a substantial increase in total data generated per flow cell (5 M vs 1.8 M reads). For the Rapid kit, the total data produced should be considered in the light of the greatly simplified sample workflow and turnaround-time.

The use of metagenomics to elucidate genomic sequences of RNA viruses directly from clinical samples has several obvious benefits in public health applications. The primary benefit over targeted methods is the hypothesis-free nature of the assay, which allows identification and genomic characterisation of novel or unexpected RNA viral agents, either as primary or coinfectants (demonstrated here in the CHIKV/DENV coinfection sample), without any prior clinical knowledge. It also removes the need for laboratory optimisation of targeted methods, such as primer or bait-probe design and testing, and is not subject to escape mutations in target sites that afflict targeted sequencing and diagnostic methods. This issue particularly relevant for highly diverse RNA viruses, such as Lassa virus, which are difficult to assess using targeted methods, without regular reappraisal \[[@r43]\].

The principal limitation of the metagenomic approach is the limit of detection. The data generated here show that viral titres as low as 10^5^ are sufficient for significant genome recovery by this method, but ZIKV is a recent example of a pathogen typically present at lower clinical titres, for which targeted methods are an absolute requirement \[[@r22],[@r23]\]. For diagnostic purposes qRT-PCR has a lower limit of detection, provided the target site is conserved in the pathogen isolate tested. Clearly no single method is most suitable for both detection and genotyping of all pathogens and each has a role to play in differing circumstances.

The ability to generate genomic data directly from patient samples is clearly of great benefit to public health (reviewed in detail \[[@r44]\]). It can be used in a routine surveillance capacity or early during suspected outbreaks to link related cases who may be missed by traditional epidemiology \[[@r45]\] and identify outbreak cases distinct from typically circulating seasonal strains, which is key in regions endemic for the pathogen in question. The use of whole genome sequences offers the greatest precision for these applications, compared with typing methods based on specific genomic regions \[[@r44]\]. Whole genome sequencing on a portable device allows this information to be generated rapidly and within the affected region \[[@r24]\], enabling timely identification of an outbreak, or allaying fears of a potential one if cases are not linked. Furthermore mutations relating to viral drug resistance or pathogenicity can be monitored \[[@r44]\]. Therefore the ability to generate near-complete viral genome sequences directly from clinical samples on a portable sequencing device has many potential applications.

Conclusions
===========

We demonstrate that across the clinically relevant range of viral loads an unexpectedly high proportion of reads generated metagenomically from CHIKV and DENV clinical samples are viral in origin. Therefore metagenomic sequencing provides an effective approach for the analysis of CHIKV and DENV genomes directly from the majority of qRT-PCR positive serum and plasma samples, without the need for culture or viral nucleic acid enrichment beyond a simple DNA digestion. We demonstrate this is equally possible on the Oxford Nanopore MinION, making metagenomic whole genome sequencing potentially feasible in the field.
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